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Purpose: Hydroclathrus clathratus is a brown marine seaweed known to possess anti-cancer, anti-herpetic, 
and anti-coagulant activities. The present study is aimed at investigating some anti-inflammatory effects of H. 
clathratus.  
Methods: We investigated the anti-inflammatory effects of the methanol extract of H. clathratus (MEHC) by 
expression of mRNA and protein using RT-PCR and Western blot analysis in lipopolysaccharide (LPS)-
stimulated BV2 microglial cells. The level of nitric oxide (NO) production was analyzed using Griess reaction. 
The release of prostaglandin E2 (PGE2) and tumor necrosis factor-α (TNF-α) were determined using sandwich 
ELISA. NF-κB activation was detected using EMSA methods. 
Results: The results obtained indicate that the extract (MEHC) inhibited LPS-induced NO, PGE2, and TNF-α 
production without any significant cytotoxicity (p < 0.05). MEHC also inhibited production of inducible NO 
synthase (iNOS), cyclooxygenase-2 (COX-2) and TNF-α mRNA in LPS-stimulated BV2 microglial cells. In 
addition, MEHC significantly reduced (p < 0.05) nuclear translocation of the nuclear factor-κB (NF-κB) 
subunits, p50 and p65, and its DNA-binding activity in LPS-stimulated BV2 microglial cells. 
Conclusion: These results suggest that MEHC suppresses the induction of TNF-α, as well as iNOS and 
COX-2 expression, by blocking LPS-induced NF-κB activation. 
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INTRODUCTION 
 
Inflammation is a beneficial host defense to 
external cellular injury or external challenge 
against infection and foreign substances such 
as bacteria and viruses that leads to the 
release of a variety of mediators [1,2]. 
However, prolonged inflammatory responses 
can be harmful, contributing to the 
pathogenesis of many diseases such as 
cartilage disease, hyperosmolarity, ischemia-
reperfusion, Alzheimer’s disease, Parkinson’s 
disease, diabetes, asthma and heart disease 
[3-5]. Although macrophages provide 
immediate defense against foreign agents in 
the infection sites [6], microglia and 
macrophages release a different variety of 
mediators, including nitric oxide (NO), 
prostaglandin E2 (PGE2), cytokines [7], 
bioactive lipids, hydrolytic enzymes, and 
reactive oxygen intermediates, all of which 
have been implicated in the pathogenesis of 
tissue damage, when they were aberrantly 
expressed in the process of prolonged 
inflammation  [8,9]. 
 
NO is generated by the inducible isoform of 
NO synthase (iNOS), which is primarily 
regulated at the expression level by 
transcriptional and post-transcriptional 
modifications [10]. Although NO has 
beneficial microbicidal, immunomodulatory, 
anti-viral, and anti-tumor effects, aberrant NO 
production can lead to inflammatory 
destruction of target tissues at the 
inflammation sites [11]. Prostaglandins also 
play a major role as mediators of the 
inflammatory response and are synthesized 
by cyclooxygenase (COX) [8]. In particular, 
inducible COX-2 is responsible for the 
production of large amounts of 
proinflammatory PGE2 in the process of 
inflammation [12]. In addition, tumor necrosis 
factor-α (TNF-α) is a proinflammatory 
cytokine important for the stimulation of the 
secretion of other inflammatory cytokines 
[13]. Thus, the inhibition of overproduction of 
NO, PGE2 and TNF-α, by restricting iNOS, 
COX-2, and TNF-α gene expression, could 
serve as a promising potential in the 
development of anti-inflammatory drugs. 
 
NF-κB has often been termed a central 
mediator in the human immune response 
[14,15]. Active NF-κB participates in the 
transcribed control of many target genes, 
including iNOS, COX-2 and TNF-α [16]. 
Thus, it has been reported that inhibitors of 
the NF-κB pathway suppress the initiation of 
the nuclear localization of the NF-κB 
subunits, p50 and p65, and control the 
switch-off of the expression of 
proinflammatory mediators such as NO, 
PGE2, and TNF-α [17,18]. Therefore, 
modulation of NF-κB activity is a good 
strategy for therapy against inflammatory 
diseases. 
 
Hydroclathrus clathratus is a brown marine 
seaweed with anti-coagulant activities [19]. 
Chemical constituents commonly isolated 
from this seaweed are the polysaccharides 
H3-a1 and H3-b1, which have anti-viral and 
anti-cancer properties [20]. Some 
components of H. clathratus specifically 
affect the growth of human acute 
promyelocytic leukemia cells (HL-60), human 
breast carcinoma cells (MCF-7), and human 
hepatocellular carcinoma cancer cells [21]. 
However, some studies have been focused 
on the antiviral and anti-cancer property of H. 
clathratus. 
 
In this study, the effects of methanol extract 
of H. clathratus (MEHC) on the expression of 
NO, PGE2 and TNF-α in lipopolysaccharide 





Preparation of MEHC 
 
MEHC was purchased from Jeju HI-Tech 
Industry Development Institute (Jeju, 
Republic of Korea). H. clathratus (stock No.; 
AP060) was collected along the Jeju Island 
coast of Korea in July, 2006. Briefly, fresh H. 
clathratus was washed three times with tap 
water to remove salt, epiphyte and sand on 
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the surface of the samples before storage -
20ºC. The frozen samples were lyophilized 
and homogenized using a grinder before 
extraction. The dried powder was extracted 




Antibodies against iNOS, COX-2, p65, and 
p50 polyclonal antibodies were purchased 
from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA). Antibody against β-actin was from 
Sigma (St. Louise, MO, USA). Peroxidase-
labeled goat anti-rabbit immunoglobulin was 
purchased from KOMA Biotechnology (Seoul, 
Republic of Korea). Lipopolysaccharide (LPS) 
and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) were purchased 
from Sigma (St. Louis, MO, USA). 
 
Cell culture and MTT assay 
 
BV2 murine microglial cells were cultured at 
37
o
C in 5% CO2 in DMEM in supplemented 
with 5% FBS and antibiotics (WelGENE Inc., 
Daegu, Republic of Korea). In all 
experiments, cells were pre-treated with the 
indicated concentrations of MEHC for 1 h 
before the addition of LPS (1 µg/ml) in serum-
free DMEM. MTT assays were used to 
determine cell viability. 
 
Nitric oxide assay 
 
Griess reagent assay was used for analyzing 
NO production. Briefly, the samples were 
mixed with equal volume of Griess reagent 
(1% sulfanilamide in 5% phosphoric acid and 
0.1% naphthylethylenediamine dihydrochlo-
ride) and then incubated at room temperature 
for 5 min. The absorbance was measured at 
540 nm on a microplate reader. Nitrite 
concentration was determined from a sodium 
nitrite standard curve 
 
Measurement of PGE2 and TNF-α 
 
Expression levels of PGE2 and TNF-α were 
measured using enzyme immunosorbent 
assay (ELISA) kit (R&D Systems, 
Minneapolis, MN, USA) according to the 
manufacturer’s instructions. 
 
Isolation of total RNA and RT-PCR 
 
Total RNA was isolated using easy-BLUE
TM
 
total RNA extraction kit (iNtRON 
Biotechnology; Sungnam, Republic of Korea). 
The total RNAs were amplified by PCR using 
the following primers:  iNOS (forward 5’-cct 
cct cca ccc tac caa gt-3’ and reverse 5’-cac 
cca aag tgcttc agt ca-3’), COX-2 (forward 5’-
aag act tgc cag gct gaa ct-3’ and reverse 5’-
ctt ctg cag tcc agg ttc aa-3’), TNF-α (forward 
5’-gcg acg tgg aac tgg cag aa-3’ and reverse 
5’-tcc atg ccg ttg gcc agg ag-3’), and β-actin 
(forward 5’-tgt gat ggt ggg aay ggg tc-3’ and 
reverse 5’-ttt gat gtc acg cac gat tt-3’). 
 
Western blot analysis 
 
Total cell extracts were prepared using PRO-
PREP protein extraction solution (iNtRON 
Biotechnology). Total cell extracts were 
separated on polyacrylamide gels and then 
standard procedures were used to transfer 
them to the nitrocellulose membranes. The 
membranes were developed using an ECL 
reagent (Amersham; Arlington Heights, IL, 
USA). 
 
Electrophoretic mobility assay (EMSA) 
 
DNA-protein binding assays were carried out 
with nuclear extract. Synthetic 
complementary NF-κB binding oligonu-
cleotides (5’-AGT TGA GGG GAC TTT CCC 
AGG C-3’) were 3’-biotinylated using the 
biotin 3’-end DNA labeling kit (Pierce; 
Rockford, IL, USA) according to the 
manufacturer’s instructions. Assays were 
performed using a Lightshift EMSA 





All bands were quantified by Scion Imaging 
software (http://www.scioncorp.com). Statis-
tical analyses were conducted using 
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SigmaPlot software (version 11.0). Values 
were presented as Mean ± SE. Significant 
differences between the groups were 
determined using two-way ANOVA. Statistical 




Effects of MEHC on cell viability 
 
To determine the effects of MEHC on cell 
viability in BV2 microglial cells, an MTT assay 
was performed 24 h after treatment with the 
indicated concentrations of MEHC in the 
presence or absence of LPS. MEHC alone in 
the range of 50 − 200 µg/ml showed no 
cytotoxic effect (Fig 1), but significant 
cytotoxicity was found at over 250 µg/ml 
MEHC in BV2 microglial cells, regardless of 
the presence of LPS. Therefore, 100 µg/ml 
MEHC was applied in further experiments. 
 
 
Fig 1: Effect of MEHC on the viability of BV2 
microglial cells. Each value is Mean ± SE (n=3).  
 
Effects of MEHC on LPS-induced NO and 
PGE2 Production 
 
In order to evaluate the anti-inflammatory 
effects of MEHC, cells were stimulated with 
LPS (1.0 µg/ml) for 24 h after pretreatment 
with 100 µg/ml MEHC for 1 h. The production 
of NO and PGE2 was analyzed using the 
Griess reaction assay and ELISA, 
respectively. NO production in cells 
stimulated with LPS was significantly higher 
(19.3 ± 1.7 µM) compared to that in untreated 
control group (5.9 ± 1.0 µM; Fig 2A). 
However, pretreatment with MEHC 
significantly suppressed LPS-induced NO 
upregulation (7.5 ± 0.6 µM). Consistent with 
the data of NO production, stimulation with 
LPS increased PGE2 production (625 ± 65 
pg/ml) by approximately 9-fold when 
compared to that in the control group (77 ± 
35 pg/ml). However, LPS-induced PGE2 
expression was decreased to approximately 
40% (245 ± 65 pg/ml) in the presence of 
MEHC. MEHC alone had no influence on the 
production of NO and PGE2. These results 
indicate that MEHC suppresses LPS-induced 
NO and PGE2 production in BV2 microglial 
cells. 
 
Fig 2: Effect of MEHC in LPS-induced NO (A) and 
PGE2 (B) release in BV2 microglial cells. Each 
value is Mean ± SE (n=3). * Significantly different 
was compared with cells treated with LPS alone (p 
< 0.05). 
 
Effects of MEHC on LPS-induced iNOS 
and COX-2 mRNA and protein 
 
To investigate whether MEHC regulates the 
expression of iNOS and COX-2 genes, we 
treated cells with 100 µg/ml of MEHC for 6 h 
in the presence of LPS, and the protein and 
mRNA expression of both iNOS and COX-2 
were determined by RT-PCR and western 
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blot analysis, respectively. RT-PCR analysis 
shows that treatment with LPS significantly 
increases the expression of iNOS and COX-2 
at 6 h (Fig. 3A), but the expression of these 
mRNAs was significantly downregulated after 
pretreatment with 100 µg/ml of MEHC. 
Although LPS significantly increased the 
expression of iNOS and COX-2 proteins, 
western blot analysis showed a decrease of 
these expression patterns in a manner similar 
to mRNA expression in the presence of 
MEHC (Fig. 3B). Taken together, these 
results indicate that MEHC suppresses the 
upregulation of LPS-stimulated iNOS and 
COX-2 expression at the transcriptional level. 
 
 
Fig. 3: Effect of MEHC on LPS induced iNOS and 
COX-2 mRNA (A) and protein (B) expression in 
BV2 microglial cells. 
 
Effects of MEHC on LPS-induced TNF-α 
production and mRNA expression 
 
We investigated whether MEHC inhibits the 
production of TNF-α and the expression of 
TNF-α mRNA in LPS-stimulated BV2 
microglial cells. Cells were pretreated with 
100 µg/ml of MEHC for 1 h before LPS 
stimulation for 24 h. The level of TNF-α in the 
culture supernatant was determined by 
ELISA. TNF-α production in cells stimulated 
with LPS was 7-fold higher (2294 ± 68 pg/ml) 
than that in the control group (311 ± 21 pg/ml; 
Fig. 4A). However, MEHC restored TNF-α 
production to a little above control level (815 
± 45 pg/ml). Consistent with the data of NO 
and PGE2 production, treatment with MEHC 
alone has no influence on TNF-α production 
(291 ± 35 pg/ml). RT-PCR data showed that 
MEHC significantly suppresses the 
expression of TNF-α mRNA in LPS-
stimulated BV2 microglial cells (Fig. 4B). 
These results indicate that MEHC regulates 
LPS-stimulated TNF-α release at the 
transcriptional level. 
 
Fig 4: Effect of MEHC on LPS-induced TNF-α 
production and TNF-α mRNA expression in BV2 
microglial cells. * Significantly different was 
compared with cells treated with LPS alone (p < 
0.05). 
 
Inhibitory effects of MEHC on LPS-
induced NF-κB activity 
 
In order to investigate whether MEHC inhibits 
proinflammatory genes such as iNOS, COX-
2, and TNF-α via suppression of NF-κB 
activity, we analyzed the specific DNA-
binding activity of NF-κB by EMSA assay. 
Stimulation with LPS caused a remarkable 
increase in binding complexes between NF-
κB and specific-binding DNA. However, 
pretreatment with MEHC for 1 h significantly 
reduced LPS-induced NF-κB activity (Fig. 
5A). LPS significantly increased the protein 
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expression of p50 and p65 in the nuclear 
compartment of BV2 microglial cells, but this 
was suppressed by treatment with MEHC 
(Fig 5B). Furthermore, N-acetyl-L-cysteine 
(NAC) was used as a potent proteasome and 
proteases inhibitor of Rel/NF-κB activity to re-
confirm those results. We conducted an RT-
PCR analysis to detect iNOS, COX-2, and 
TNF-α mRNA expression in the presence of 
NAC. As we expected, NAC inhibited the 
expression of LPS-stimulated iNOS, COX-2, 
and TNF-α expression at the transcription 
level (Fig 5C). These results indicate that 
MEHC inhibits the expression of 
proinflammatory genes via suppression of 









Pathological agents like bacteria and fungi 
stimulate microglia and macrophages leading 
to the induction of mediators relevant to the 
inflammatory process [22]. In particular, LPS 
strongly leads to the activation of several 
transduction pathways and secretion of 
various inflammatory mediators [23]. The 
results obtained in this study revealed that 
MEHC inhibits LPS-induced NO and PGE2 
production by suppressing iNOS and COX-2 
expression in BV2 microglial cells. MEHC 
also decreases TNF-α production by 
suppressing its mRNA expression. 
Furthermore, we found that these effects 
were induced via suppression of NF-κB 
activity. Taken together, these data indicate 
that MEHC inhibits LPS-induced 
proinflammatory mediators such as NO, 
PGE2, and TNF-α via suppression of NF-κB 
activity. 
 
NO is significantly produced in microglia and 
macrophages, and it normally is an important 




relaxation and neurotransmission [24]. 
However, experimental studies have also 
confirmed that NO overproduction causes 
severe inflammatory diseases such as septic 
shock [25]. Thus, many researchers have 
tried to regulate NO production so as to 
overcome these imbalances within the 
immune system. In the present study, we 
found that MEHC is a good regulator for 
downregulation of NO production. These 
results imply that MEHC may be a potent 
candidate for inhibiting NO production and 
inflammatory diseases. PGE2, which results 
from overproduction of the COX-2 gene, is 
particularly responsible for various biological 
events such as neuronal function, female 
reproduction, vascular hypertension, 
tumorigenesis, kidney function and 
inflammation [26]. Accumulating evidence 
confirms the effects of COX-2 and PGE2 as 
potential therapeutic targets for treating 
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inflammatory diseases [27, 28]. Furthermore, 
TNF-α is a cytokine involved in the 
inflammatory and destructive process 
common to several human inflammatory 
diseases, and overproduction of TNF-α 
switches on the signaling pathways that 
change the cell functions of LPS-stimulated 
microglia and macrophages [29]. Due to this 
signaling activity, anti-TNF-α therapy has 
been broadly introduced to treat various 
inflammatory diseases [13]. Therefore, 
suppressing NO, PGE2 and TNF-α production 
by inhibiting their regulatory genes could be a 
very important therapeutic target for 
developing anti-inflammatory agents.  
 
NF-κB is a ubiquitous and rapidly responsive 
cellular transcription factor which is strongly 
activated by LPS and TNF-α under various 
pathological conditions [30]. In non-stimulated 
cells, NF-κB is present in the cytosol where it 
is complexed with inhibitor IκB. Activation of 
NF-κB depends on the signal-induced 
phosphorylation of IκB by specific IκB 
kinases, which initiates the inhibitor's 
conjugation to ubiquitin and subsequent 
degradation by the proteasome [31]. In this 
study, we found that MEHC suppresses LPS-
induced nuclear translocation of p65 and p50 
as well as the specific DNA-binding activity of 
NF-κB. In addition, the expression of iNOS, 
COX-2 and TNF-α mRNA significantly 
suppressed in the presence of NAC. These 
results suggest that MEHC inhibits LPS-
induced NF-κB activity by suppressing the 





This study confirmed that MEHC has anti-
inflammatory activity, which has an influence 
on the regulation of NO, PGE2, and TNF-α 
expression by suppressing NF-κB activity. 
Therefore, MEHC may be a safe and 
effective therapeutic agent for the regulation 




This study was supported by a grand from 
Jeju Sea Grant, Republic of Korea. We are 
also thankful to Prof. I.W. Choi (Inje 
University, Busan, Republic of Korea) 




1. Noble PW, Jiang D. Matrix regulation of lung injury, 
inflammation, and repair: the role of innate 
immunity. Proc Am Thorac Soc 2006; 3: 401–
404. 
2. Bensinger SJ, Tontonoz P. A Nurr1 pathway for 
neuroprotection. Cell 2009; 137: 26–28. 
3. Lee JW, Lee MS, Kim TH, Lee HJ, Hong SS, Noh YH, 
Hwang BY, Ro JS, Hong JT. Inhibitory effect 
of inflexinol on nitric oxide generation and 
iNOS expression via inhibition of NF-κB 
activation. Mediators Inflamm 2007; 93148–
93157. 
4. Pacher P, Beckman JS, Liaudet L. Nitric oxide and 
peroxynitrite in health and disease. Physiol 
Rev 2007; 87: 315–424. 
5. Glass CK, Saijo K, Winner B, Marchetto MC, Gage 
FH. Mechanisms underlying inflammation in 
neurodegeneration. Cell 2010; 140: 918–934. 
6. Ellermann-Eriksen S. Macrophages and cytokines in 
the early defence against herpes simplex 
virus. Virol J 2005; 2: 59. 
7. Conquy MA, Cavaillon JM. Stress molecules in sepsis 
and systemic inflammatory response 
syndrome. FEBS Lett 2007; 581: 3723–3733. 
8. Whiteman M, Spencer JPE, Zhu YZ, Armstrong JS, 
Schantz JT. Peroxynitrite-modified collagen-II 
induces p38/ERK and NF-κB-dependent 
synthesis of prostaglandin E2 and nitric oxide 
in chondrogenically differentiated 
mesenchymal progenitor cells. Osteoarthritis 
Cartilage 2006; 14: 460–470. 
9. Schetter AJ, Heegaard NH, Harris CC. Inflammation 
and cancer: interweaving microRNA, free 
radical, cytokine and p53 pathways. 
Carcinogenesis 2010; 31: 37–49. 
10. Pannu R, Singh I. Pharmacological strategies for the 
regulation of inducible nitric oxide synthase: 
Neurodegenerative versus neuroprotective 
mechanisms. Neurochem Int 2006; 49: 170–
182. 
11. Kolios G, Valatas V, Ward SG. Nitric oxide in 
inflammatory bowel disease: a universal 
messenger in an unsolved puzzle. 
Immunology 2004; 113: 427–437. 
12. Sudha KN, Shakira M, Prasanthi P, Sarika N, Kumar 
ChN, Babu PA. Virtual screening for novel 
COX-2 inhibitors using the ZINC database. 
Bioinformation 2008; 2: 325–329. 
13. Popa C, Netea MG, van Riel PL, van der Meer JW, 
Stalenhoef AF. The role of TNF-α in chronic 
Jayasooriya et al  
Trop J Pharm Res, December 2011;10 (6): 730 
inflammatory conditions, intermediary 
metabolism, and cardiovascular risk. J Lipid 
Res 2007; 48: 751–762. 
14. Pahl HL. Activators and target genes of Rel/NF-κB 
transcription factors. Oncogene 1999; 18: 
6853–6866. 
15. Epinat JC, Gilmore TD. Diverse agents act at 
multiple levels to inhibit the Rel/NF-κB signal 
transduction pathway. Oncogene 1999; 18: 
6896–6909. 
16. Li X, Stark GR. NFκB-dependent signaling pathways. 
Exp Hematol 2002; 30: 285–296. 
17. Lee JH, Jung HS, Giang PM, Jin X, Lee S, Son PT, 
Lee D, Hong YS, Lee K, Lee JJ. Blockade of 
nuclear factor-κB signaling pathway and anti-
inflammatory activity of cardamomin, a 
chalcone analog from Alpinia conchigera. J 
Pharmacol Exp Ther 2006; 316: 271–278. 
18. Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-
Ramos MS, Shinn P, Van Leer D, Leister W, 
Austin CP, Xia M. Identification of known 
drugs that act as inhibitors of NF-κB signaling 
and their mechanism of action. Biochem 
Pharmacol 2010; 79: 12721280. 
19. Wang H, Ooi VEC, Ang PO Jr. Antiviral 
polysaccharides isolated from Hong Kong 
brown seaweed Hydroclathrus clathratus. Sci 
China Life Sci 2007; 50: 611–618. 
20. Wang H, Ooi VEC, Ang PO Jr. Anti-herpesviral 
property and mode of action of a 
polysaccharide from brown seaweed 
(Hydroclathrus clathratus). World J Microbiol 
Biotechnol 2010; 26: 1703–1713. 
21. Wang H, Chiu LCM, Ooi VEC, Ang PO Jr. A potent 
antitumor polysaccharide from the edible 
brown seaweed Hydroclathrus clathratus. 
Botanica Marina 2010; 53: 265–274. 
22. Palsson-McDermott EM, O’Neill LA. Signal 
transduction by the lipopolysaccharide 
receptor, Toll-like receptor-4. Immunology 
2004; 113: 153–162. 
23. Sassa MF, Saturi AET, Souza LF, Ribeiro LCDA, 
Sgarbi DBDG, Carlos IZ. Response of 
macrophage Toll-like receptor 4 to a 
Sporothrix schenckii lipid extract during 
experimental sporotrichosis. Immunology 
2009; 128: 301–309. 
24. Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G. Nitric 
oxide in health and disease of the respiratory 
system. Physiol Rev 2004; 84: 731–765. 
25. Massi D, Nisi MCD, Franchi A, Mourmouras V, 
Baroni G, Panelos J, Santucci M, Miracco C. 
Inducible nitric oxide synthase expression in 
melanoma: implications in lymphan-
giogenesis. Mod Pathol 2009; 22: 21–30. 
26. Zhang D, Hu X, Qian L, Wilson B, Lee C, Flood P, 
Langenbach R, Hong JS. Prostaglandin E2 
released from activated microglia enhances 
astrocyte proliferation in vitro. Toxicol Appl 
Pharmacol 2009; 238: 64–70. 
27. Kunz T, Marklund N, Hillered L, Oliw EH. 
Cyclooxygenase-2, prostaglandin synthases, 
and prostaglandin H2 metabolism in traumatic 
brain injury in the rat. J Neurotrauma 2002; 
19: 1051–1064. 
28. Korotkova M, Westman M, Gheorghe KR, af Klint E, 
Trollmo C, Ulfgren AK, Klareskog L, 
Jakobsson PJ. Effects of antirheumatic 
treatments on the prostaglanding E2 
biosynthetic pathway. Arthritis Rheum 2005; 
52: 3439–3447. 
29. Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru 
CD, Adair B, Fabbri M, Alder H, Liu CG, Calin 
GA, et al. Modulation of miR-155 and miR-
125b levels following lipopolysaccharide/ 
TNF-α stimulation and their possible roles in 
regulating the response to endotoxin shock. J 
Immunol 2007; 179: 5082–5089. 
30. Kim HJ, Hawke N, Baldwin AS. NF-κB and IKK as 
therapeutic targets in cancer. Cell Death Differ 
2006; 13: 738–747. 
31. Karin M, Ben-Neriah Y. Phosphorylation meets 
ubiquitination: the control of NF-κB activity. 
Annu Rev Immunol 2000; 18: 621–663. 
 
